Publicacións nas que colabora con AMALIA LAMANA DOMÍNGUEZ (12)

2024

  1. Vasoactive intestinal peptide exerts an osteoinductive effect in human mesenchymal stem cells

    BioFactors

2022

  1. Human CD4+CD45RA+ T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide

    International Journal of Molecular Sciences, Vol. 23, Núm. 4

  2. VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures

    International journal of molecular sciences, Vol. 23, Núm. 15

2021

  1. The neuropeptide vip limits human osteoclastogenesis: Clinical associations with bone metabolism markers in patients with early arthritis

    Biomedicines, Vol. 9, Núm. 12

2020

  1. A clinical approach for the use of VIP axis in inflammatory and autoimmune diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 1

  2. Comparative Study of Senescent Th Biomarkers in Healthy Donors and Early Arthritis Patients. Analysis of VPAC Receptors and Their Influence

    Cells, Vol. 9, Núm. 12

2019

  1. An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance

    Frontiers in Endocrinology, Vol. 10

2018

  1. Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Clinical relevance of VPAC1 receptor expression in early arthritis: Association with IL-6 and disease activity

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity

    Journal of Molecular Neuroscience, Vol. 56, Núm. 3, pp. 577-584

2014

  1. Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis

    PLoS ONE, Vol. 9, Núm. 1

2013

  1. Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis.

    ARTHRITIS AND RHEUMATISM